Skip to main content
. 2016 May 10;2(1):e000213. doi: 10.1136/rmdopen-2015-000213

FigureĀ 2.

FigureĀ 2

SIRs for malignancy for (A) US patients and (B) non-US patients (tocilizumab all-exposure population). N Obs, number observed; SIR, standardised incidence ratio.